Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial
Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy in early relapsed multiple myeloma can provide deep and durable responses for eligible patients, though patient selection, timing of referral, manufacturing logistics, and management of adverse effects remain important considerations in optimizing outcomes.
EP: 1.Current Strategies for Frontline Therapy in Transplant-Preferred NDMM
EP: 2.Brief Overview of PERSEUS, IsKia, and CASSIOPEIA Clinical Trials
EP: 3.Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations
EP: 4.Insights of MAIA, BENEFIT, and IMROZ Trials on Frontline Treatment for Transplant Not-Preferred NDMM
EP: 5.Initial Impressions of the CEPHEUS Clinical Trial in Transplant Not-Preferred NDMM
EP: 6.Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial
Video content above is prompted by the following:
- What has been your experience with using CAR T-cell therapy in patients with early relapsed multiple myeloma?
- How does CAR T-cell therapy compare with other available second-line treatments?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
